Who is sponsoring NCT05715814?

NCT05715814 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT05715814?

Interventions in NCT05715814: Empagliflozin 25 MG.

What condition does NCT05715814 study?

NCT05715814 studies Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction, Residual Kidney Function.

Is NCT05715814 still recruiting?

NCT05715814 is currently recruiting now. Last updated 31 January 2025.

Last reviewed 2025-01-31 · How we verify

NCT05715814: CANARY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Recruiting now Phase 3 Last updated 31 January 2025

What this trial tests

Phase 3 trial testing Empagliflozin 25 MG in Peritoneal Dialysis Complication in 20 participants. Currently enrolling.

Timeline

1 September 2024

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 September 2024
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	1 location across Canada

Drugs / interventions tested

Empagliflozin 25 MG — full drug profile →

Conditions studied

Peritoneal Dialysis Complication — all drugs for Peritoneal Dialysis Complication →
End Stage Kidney Disease — all drugs for End Stage Kidney Disease →
Sodium-glucose Co-transporter-2 Inhibitors — all drugs for Sodium-glucose Co-transporter-2 Inhibitors →
Kidney Dysfunction — all drugs for Kidney Dysfunction →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Peritoneal Dialysis Complication or End Stage Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.
Preda A, Montecucco F, Carbone F, Carbone F, et al · · 2024 · cited 76× · PMID 38456601 · DOI 10.1093/cvr/cvae047
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Siddiqui R, Obi Y, Dossabhoy NR, Shafi T. · · 2024 · cited 15× · PMID 38913113 · DOI 10.1007/s11906-024-01314-3
Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications.
León-Jiménez D, Sridhar VS, López-Mendoza M, Scholtes RA, et al · · 2025 · cited 7× · PMID 40008354 · DOI 10.1093/ckj/sfae370
Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic and Non-Diabetic Patients with Advanced Chronic Kidney Disease in Peritoneal Dialysis on Residual Kidney Function: In Real-World Data.
Moral Berrio E, De La Flor JC, Arambarri Segura M, Rodríguez-Doyágüez P, et al · · 2024 · cited 4× · PMID 39202480 · DOI 10.3390/medicina60081198
SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art.
Minutolo R, Ruotolo C, Conte G, Borrelli S. · · 2026 · cited 2× · PMID 41487902 · DOI 10.1093/ckj/sfaf350
Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far?
Duni A, Tsavourelou P, Triantafyllidou M, Gkika L, et al · · 2025 · PMID 41635419 · DOI 10.3389/fcdhc.2025.1759340
Role of SGLT-2 Inhibitors in Ultrafiltration Failure in Peritoneal Dialysis: A Narrative Review.
Riedl Khursigara M, Liu P, Kaur R, Mavrakanas TA. · · 2024 · PMID 39502166 · DOI 10.1177/20543581241293500

Verify or expand the search:

Other trials of Empagliflozin 25 MG

Trials testing the same drug.

NCT07053306 — SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia · Phase 1 · recruiting
NCT07053293 — SGLT2i, Hepatic Glucose Production, and SNS · EARLY_PHASE1 · recruiting
NCT06578676 — To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults · Phase 1 · recruiting
NCT06249932 — Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease · Phase 4 · recruiting
NCT06249945 — EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease · Phase 4 · recruiting

Other recruiting trials for Peritoneal Dialysis Complication

Currently open trials in the same condition.

NCT06483074 — Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients · Phase 2 · recruiting
NCT06398977 — Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients · NA · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05715814 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 31 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05715814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing